What is Bodhi Tree Biotechnology Inc's earnings per share (EPS)?

Bodhi Tree Biotechnology Inc (BDTB) reported diluted earnings per share of $-0.01 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bodhi Tree Biotechnology Inc Financials

BDTB

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE September

This page shows Bodhi Tree Biotechnology Inc (BDTB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BDTB FY2025 2026-05-14

BDTB currently operates more like a cash-funded corporate shell than a self-supporting business, with overhead overwhelming activity.

With $109K of cash and $0 liabilities, financial pressure is not coming from leverage or creditor claims on the balance sheet. Reported revenue of $17K sits far below the operating cash outflow of -$150K, which shows the entity is currently using stored cash to support its existence rather than turning operations into cash.

Selling, general and administrative expense of $165K dwarfed revenue of $17K, suggesting the company is carrying a public-company or platform cost base that current activity does not cover. The cash-heavy asset base means results today are shaped more by whether activity can absorb fixed overhead than by asset productivity.

Operating cash outflow of -$150K closely matched the net loss of -$150K, so the reported loss is showing up as real cash consumption rather than being softened by noncash accounting items. That makes the cash balance a funding source, not merely a reserve, for the current operating setup.

Financial Health Signals

Financial Profile 17/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Bodhi Tree Biotechnology Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Bodhi Tree Biotechnology Inc has an operating margin of -868.3%, meaning the company retains $-868 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.

Leverage

100

Bodhi Tree Biotechnology Inc carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Returns

Bodhi Tree Biotechnology Inc generates a -125.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.

Earnings Quality Low Quality

1.00x

For every $1 of reported earnings, Bodhi Tree Biotechnology Inc generates $1.00 in operating cash flow (-$150K OCF vs -$150K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-73809.0x

Bodhi Tree Biotechnology Inc earns $-73809.0 in operating income for every $1 of interest expense (-$148K vs $2). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$17K

Bodhi Tree Biotechnology Inc generated $17K in revenue in fiscal year 2025.

EBITDA

N/A

Net Income

-$150K

Bodhi Tree Biotechnology Inc reported -$150K in net income in fiscal year 2025.

EPS (Diluted)

$-0.01

Bodhi Tree Biotechnology Inc earned $-0.01 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$109K

Bodhi Tree Biotechnology Inc held $109K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

25M

Bodhi Tree Biotechnology Inc had 25M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

N/A

Operating Margin

-868.3%

Bodhi Tree Biotechnology Inc's operating margin was -868.3% in fiscal year 2025, reflecting core business profitability.

Net Margin

-880.4%

Bodhi Tree Biotechnology Inc's net profit margin was -880.4% in fiscal year 2025, showing the share of revenue converted to profit.

Return on Equity

-125.6%

Bodhi Tree Biotechnology Inc's ROE was -125.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

BDTB Income Statement

Metric	FY25
Revenue	$17K
Cost of Revenue	N/A
Gross Profit	N/A
R&D Expenses	N/A
SG&A Expenses	$165K
Operating Income	-$148K
Interest Expense	$2
Income Tax	$2K
Net Income	-$150K
EPS (Diluted)	$-0.01

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$15K	$0	N/A	N/A	$0-100.0%	$5K	N/A	$15K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$43K-18.9%	$53K	N/A	$20K-61.7%	$52K-25.2%	$70K	N/A	$5K
Operating Income	-$28K+47.2%	-$53K	N/A	-$20K+61.7%	-$52K+19.4%	-$65K	N/A	$10K
Interest Expense	$2+100.0%	$1	N/A	$10.0%	$1	N/A	N/A	N/A
Income Tax	$1K	N/A	N/A	$800-36.0%	$1K	N/A	N/A	N/A
Net Income	-$29K+44.9%	-$53K	N/A	-$21K+61.1%	-$53K+17.5%	-$65K	N/A	$10K
EPS (Diluted)	$0.00+100.0%	$-0.01	N/A	$0.00	$0.00	$0.00	N/A	$0.00

BDTB Balance Sheet

Metric	FY25
Total Assets	$119K
Current Assets	N/A
Cash & Equivalents	$109K
Inventory	N/A
Accounts Receivable	N/A
Goodwill	N/A
Total Liabilities	$0
Current Liabilities	N/A
Long-Term Debt	N/A
Total Equity	$119K
Retained Earnings	-$212K

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$41K-41.9%	$70K-41.5%	$119K-8.2%	$130K-13.8%	$151K	N/A	$269K	N/A
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$23K-52.0%	$47K-56.7%	$109K-8.5%	$120K-17.1%	$144K-25.8%	$194K-25.1%	$260K+272.0%	$70K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4K0.0%	$4K	$0	$0	$0	N/A	$500	N/A
Current Liabilities	$4K0.0%	$4K	N/A	N/A	N/A	N/A	$500	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$37K-44.1%	$66K-44.4%	$119K-8.2%	$130K-13.8%	$151K-26.2%	$204K-24.1%	$269K+351.0%	$60K
Retained Earnings	-$294K-11.0%	-$265K-25.0%	-$212K-5.3%	-$201K-11.5%	-$180K	N/A	-$62K	N/A

BDTB Cash Flow Statement

Metric	FY25
Operating Cash Flow	-$150K
Capital Expenditures	N/A
Free Cash Flow	N/A
Investing Cash Flow	N/A
Financing Cash Flow	N/A
Dividends Paid	N/A
Share Buybacks	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$25K+60.3%	-$62K-513.5%	-$10K+59.0%	-$25K+50.8%	-$50K+23.2%	-$65K+28.3%	-$91K-569.1%	$19K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	$281K+18618.7%	$2K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BDTB Financial Ratios

Metric	FY25
Gross Margin	N/A
Operating Margin	-868.3%
Net Margin	-880.4%
Return on Equity	-125.6%
Return on Assets	-125.6%
Current Ratio	N/A
Debt-to-Equity	0.00
FCF Margin	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-186.2%	N/A	N/A	N/A	N/A	-1295.5%	N/A	64.8%
Net Margin	-194.6%	N/A	N/A	N/A	N/A	-1295.5%	N/A	64.8%
Return on Equity	-78.9%+1.1pp	-80.0%	N/A	-16.0%+19.5pp	-35.5%-3.7pp	-31.8%	N/A	16.3%
Return on Assets	-72.1%+3.9pp	-75.9%	N/A	-16.0%+19.5pp	-35.5%	N/A	N/A	N/A
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	0.09+0.0	0.05+0.1	0.000.0	0.000.0	0.00	N/A	0.00	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

What is Bodhi Tree Biotechnology Inc's annual revenue?

Bodhi Tree Biotechnology Inc (BDTB) reported $17K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Bodhi Tree Biotechnology Inc profitable?

No, Bodhi Tree Biotechnology Inc (BDTB) reported a net income of -$150K in fiscal year 2025, with a net profit margin of -880.4%.

What is Bodhi Tree Biotechnology Inc's operating margin?

Bodhi Tree Biotechnology Inc (BDTB) had an operating margin of -868.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Bodhi Tree Biotechnology Inc's net profit margin?

Bodhi Tree Biotechnology Inc (BDTB) had a net profit margin of -880.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Bodhi Tree Biotechnology Inc's return on equity (ROE)?

Bodhi Tree Biotechnology Inc (BDTB) has a return on equity of -125.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bodhi Tree Biotechnology Inc's operating cash flow?

Bodhi Tree Biotechnology Inc (BDTB) generated -$150K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bodhi Tree Biotechnology Inc's total assets?

Bodhi Tree Biotechnology Inc (BDTB) had $119K in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Bodhi Tree Biotechnology Inc have outstanding?

Bodhi Tree Biotechnology Inc (BDTB) had 25M shares outstanding as of fiscal year 2025.

What is Bodhi Tree Biotechnology Inc's debt-to-equity ratio?

Bodhi Tree Biotechnology Inc (BDTB) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bodhi Tree Biotechnology Inc's return on assets (ROA)?

Bodhi Tree Biotechnology Inc (BDTB) had a return on assets of -125.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bodhi Tree Biotechnology Inc's cash runway?

Based on fiscal year 2025 data, Bodhi Tree Biotechnology Inc (BDTB) had $109K in cash against an annual operating cash burn of $150K. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Are Bodhi Tree Biotechnology Inc's earnings high quality?

Bodhi Tree Biotechnology Inc (BDTB) has an earnings quality ratio of 1.00x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Bodhi Tree Biotechnology Inc cover its interest payments?

Bodhi Tree Biotechnology Inc (BDTB) has an interest coverage ratio of -73809.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Bodhi Tree Biotechnology Inc?

Bodhi Tree Biotechnology Inc (BDTB) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.